Gilead Sciences Inc (GILD)

64.31
0.38 0.59
NASDAQ : Health Care
Prev Close 64.69
Open 64.73
Day Low/High 64.23 / 64.79
52 Wk Low/High 77.92 / 120.37
Volume 5.93M
Avg Volume 7.98M
Exchange NASDAQ
Shares Outstanding 1.31B
Market Cap 84.10B
EPS 10.10
P/E Ratio 6.80
Div & Yield 2.08 (3.20%)

Latest News

Barclays Remains Bullish on Gilead

Barclays Remains Bullish on Gilead

Shares of the biopharmaceutical firm are lower by over 10% year-to-date.

See How Gilead Sciences Ranks Among Analysts' Top Picks With Strong Buyback Activity

See How Gilead Sciences Ranks Among Analysts' Top Picks With Strong Buyback Activity

A study of analyst recommendations at the major brokerages shows that Gilead Sciences, Inc. is the #56 broker analyst pick among those stocks screened by The Online Investor for strong stock buyback activity.

Trump Resurrects Talk of 10% Tax Holiday in Big Gift to Tech

Trump Resurrects Talk of 10% Tax Holiday in Big Gift to Tech

President Trump delivered some good news to tech giants and other corporations hoarding loads of cash abroad -- a 10% repatriation holiday is back on the table.

Arconic, Cedar Fair, Gilead: 'Mad Money' Lightning Round May 5 2017

Arconic, Cedar Fair, Gilead: 'Mad Money' Lightning Round May 5 2017

A roundup of Cramer's comments on stocks of interest to viewers.

Back to Earnings Next Week: Cramer's 'Mad Money' Recap (Friday 5/5/17)

Back to Earnings Next Week: Cramer's 'Mad Money' Recap (Friday 5/5/17)

With the Fed and the healthcare vote out of the way, markets will focus on earnings in the week ahead.

Group Stink; Good, the Bad and the Ugly: Doug Kass' Views

Group Stink; Good, the Bad and the Ugly: Doug Kass' Views

Doug Kass shares his thoughts on Facebook, Allergan and Apple.

Gilead Sciences To Present At The Bank Of America Merrill Lynch Healthcare Conference On Thursday, May 18

Gilead Sciences To Present At The Bank Of America Merrill Lynch Healthcare Conference On Thursday, May 18

Gilead Sciences, Inc. (Nasdaq: GILD) today announced that Kevin Young CBE, Gilead's Chief Operating Officer, and Norbert W.

Dow Holds Lower After House Passes Health Care Vote, Crude Falls

Dow Holds Lower After House Passes Health Care Vote, Crude Falls

Stocks move mostly lower on Thursday after the House passes a bill to repeal and replace the Affordable Care Act.

No Gilead Sciences M&A Yet, but CEO Offers Hint of Deals to Come

No Gilead Sciences M&A Yet, but CEO Offers Hint of Deals to Come

Gilead's first-quarter conference call delivered another opportunity for analysts to ask management, 'Who are you going to buy and when?'

Fed Says First-Quarter Slowdown 'Transitory;' S&P 500, Nasdaq Close Slightly Lower

Fed Says First-Quarter Slowdown 'Transitory;' S&P 500, Nasdaq Close Slightly Lower

The central bank's faith in the economic recovery lifts some of the weight on Wall Street Wednesday. Stocks close mostly lower, though well off their lows.

S&P 500 Lower After Fed Leaves Rates Unchanged, Dow Turns Higher

S&P 500 Lower After Fed Leaves Rates Unchanged, Dow Turns Higher

Stocks hold mostly lower on Wednesday after the Federal Reserve's policy-making group decides to leave its federal funds rate unchanged.

Earnings: Assessing 3 Biotech Bellwethers

Earnings: Assessing 3 Biotech Bellwethers

How did Celgene, AbbVie and Gilead fare last quarter?

Stock Losses Deepen as Oil Tumbles, Apple Falls and Wall Street Awaits the Fed

Stock Losses Deepen as Oil Tumbles, Apple Falls and Wall Street Awaits the Fed

Stock losses deepen on Wednesday morning after crude oil turns negative and a decision from the Federal Reserve looms.

Stock Futures Lower After Apple Misses, Private-Sector Hiring Slows

Stock Futures Lower After Apple Misses, Private-Sector Hiring Slows

Stock futures are lower on Wednesday morning after Apple posts weaker quarterly iPhone sales than analysts had anticipated.

Trader's Daily Notebook: Market Could Use Jolt From Fed, Earnings

Trader's Daily Notebook: Market Could Use Jolt From Fed, Earnings

Nearly anything associated with oil and gas drilling gets crushed.

Gilead Stock Drops Following Earnings Miss

Gilead Stock Drops Following Earnings Miss

Gilead also missed analysts' revenue expectations for the first quarter.

Gilead Sciences Announces Second Quarter 2017 Dividend

Gilead Sciences Announces Second Quarter 2017 Dividend

Gilead Sciences, Inc. (Nasdaq:GILD) today announced that the company's Board of Directors has declared a cash dividend of $0.

Gilead Sciences Announces First Quarter 2017 Financial Results

Gilead Sciences Announces First Quarter 2017 Financial Results

Gilead Sciences, Inc. (Nasdaq: GILD) announced today its results of operations for the first quarter ended March 31, 2017.

5 Things You Must Know Before the Market Opens Tuesday

5 Things You Must Know Before the Market Opens Tuesday

U.S. stock futures point to a mixed start for Wall Street on Tuesday ahead of a meeting of the Federal Reserve and earnings from tech giant Apple.

European Stocks Edge Higher; U.S. Tech Sector Earnings In Focus

European Stocks Edge Higher; U.S. Tech Sector Earnings In Focus

European stocks posted modest gains at the open of trading Tuesday as investors returned from a May holiday weekend to stronger U.S. tech sector earnings and improving geopolitical sentiment.

European Stocks Called Higher After U.S. Tech Earnings Lift Asia Markets

European Stocks Called Higher After U.S. Tech Earnings Lift Asia Markets

European stocks are set to open higher Tuesday as investors return from a May holiday weekend to stronger U.S. tech sector earnings and improving geopolitical sentiment.

Week Ahead: Apple Earnings, Jobs Report on the Docket in Busy Start to May

Week Ahead: Apple Earnings, Jobs Report on the Docket in Busy Start to May

May kicks off with a busy first week filled with earnings, monetary policy and a snapshot of the health of the economy.

Good, the Bad and the Ugly; What Troubles Me: Doug Kass' Views

Good, the Bad and the Ugly; What Troubles Me: Doug Kass' Views

Doug Kass shares his thoughts on Facebook, Allergan and Eli Lilly.

First Solar, NetApp, Gilead Could Profit Most on Trump's Tax Plan

First Solar, NetApp, Gilead Could Profit Most on Trump's Tax Plan

Apple isn't the biggest winner from Trump's plans for a tax holiday. These three stocks are...

Gilead, NetApp, First Solar Could Profit Most on Trump's Tax Plan

Gilead, NetApp, First Solar Could Profit Most on Trump's Tax Plan

Apple isn't the biggest winner from Trump's plans for a tax holiday. These three stocks are. ...

Surveying the NASH Drug Landscape

Surveying the NASH Drug Landscape

Biotech investors should keep a close eye on the progress in this huge potential market.

Gilead Announces Scientific Presentations Demonstrating Efficacy Of Harvoni® (Ledipasvir/Sofosbuvir) In Special Patient Populations With HCV Infection

Gilead Announces Scientific Presentations Demonstrating Efficacy Of Harvoni® (Ledipasvir/Sofosbuvir) In Special Patient Populations With HCV Infection

Gilead Sciences, Inc. (Nasdaq: GILD) today announced results from two Phase 2 studies evaluating Harvoni ® (ledipasvir 90 mg/sofosbuvir 400 mg, LDV/SOF) tablets in chronic hepatitis C virus (HCV)-infected patient...